XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for XTL Biopharmaceuticals Ltd. in 2026.
Earnings calendar
Next earnings date
—
Not scheduled
EPS estimate
—
Revenue estimate
—
Past earnings
No earnings history available.
Dividend calendar
No dividend history available.
Company profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Exchange
- Nasdaq
- CEO
- Noam Band
- Employees
- 10
- IPO date
- 01 Sep 2005
- ISIN
- US98386D3070
- Website
- xtlbio.com
Frequently asked questions
Where is XTL Biopharmaceuticals Ltd. stock listed?
XTL Biopharmaceuticals Ltd. (XTLB) is listed on Nasdaq.